Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cell Therapy for Severe COVID-19
NCT04392778Phase 2Completed
- Sponsor
- Dr. Sadi Konuk Training and Research Hospital
- Start
- Apr 2020
- Primary completion
- Nov 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of human umbilical cord mesenchymal stem cells in coronavirus disease 2019 (COVID-19) and pneumonia (3 arms), sponsored by Dr. Sadi Konuk Training and Research Hospital. Primary endpoint: Clinical improvement at 3 months. Started Apr 2020; status: completed.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on NCT04392778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04392778.